EUCTR2005-000594-22-HU进行中（未招募）不适用
A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/RTV versus LPV/RTV in treatment-experienced HIV-1 infected subjects.
Tibotec Pharmaceuticals Limited0 个研究点目标入组 500 人开始时间: 2005年4月18日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female subjects, aged 18 years or older.
- •2. Subjects with documented HIV-1 infection.
- •3. Treatment with HAART regimen for at least 12 weeks.
- •Note: Structured treatment interruption of a minimum of 4 weeks is allowed.
- •Note: HAART (Highly Active Antiretroviral Therapy) is defined as potent anti-HIV treatment usually including a combination of three or more drugs with activity against HIV whose purpose is to reduce viral load to undetectable. This regimen usually includes treatment with at least 2 NRTIs in combination with at least 1 additional ARV from the NNRTI and/or PI class.
- •4. Prescreening and screening plasma HIV-1 RNA > 1000 copies/mL (assayed by RNA PCR standard specimen procedure).
- •Note: If no documented prescreening viral load is available (taken at least 12 weeks after starting the current HAART regimen), a prescreening visit should be scheduled.
- •5. Subjects have voluntarily signed the informed consent form.
- •6. Subjects can comply with the protocol requirements.
- •7. General medical condition, in the investigator’s opinion, does not interfere with the
- •assessments and the completion of the trial.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Presence of any currently active AIDS defining illness (Category C conditions according to the CDC Classification System for HIV Infection 1993) with the following exceptions:
- •- Stable cutaneous Kaposi’s Sarcoma (i.e., no internal organ involvement other
- •than oral lesions) that is unlikely to require any form of systemic therapy during the trial time period.
- •- Wasting syndrome.
- •Note: Primary and secondary prophylaxis for an AIDS defining illness is allowed in case the medication used is not part of the disallowed medication.
- •2. Current or past alcohol and/or drug use which, in the investigator's opinion, could
- •compromise the subject's safety or adherence to the study protocol procedures.
- •3. Subjects for whom an investigational ARV is part of the current regimen, with the following exceptions if applicable (depending on local regulatory approval): tenofovir, emtricitabine, atazanavir, fosamprenavir.
- •Note: Participation in observational studies where no treatment is administered is
- •allowed (if approved by sponsor).
- •4. Previous or current use of LPV, enfuvirtide (T-20), tipranavir and TMC114.
- •5. Use of any non-ARV investigational agents within 90 days prior to screening.
- •6. Use of disallowed concomitant therapy.
- •7. Life expectancy of less than 6 months.
- •8. Pregnant or breast-feeding.
- •9. Female subject of childbearing potential without use of effective non-hormonal birth control methods or not willing to continue practicing these birth control methods for at least 14 days after the end of the treatment period.
- •Note: Hormonal based contraception may not be reliable when taking TMC114,
- •therefore to be eligible for this study women of childbearing potential should
- •(1) use a double barrier method to prevent pregnancy (i.e., use a condom with
- •either diaphragm or cervical cap), or,
- •(2) use hormonal based contraceptives in combination with a barrier contraceptive (i.e., male condom, diaphragm or cervical cap or female condom), or,
- •(3) use an intra uterine device (IUD) in combination with a barrier contraceptive
- •(i.e., male condom, diaphragm or cervical cap or female condom), or,
- •(4) be non-heterosexually active, practice sexual abstinence or have a vasectomized partner (confirmed sterile).
- •Note: Women who are postmenopausal for at least 2 years, women with total
- •hysterectomy and women with tubal ligation are considered of non-childbearing
- •10. Subjects with clinical or laboratory evidence of significantly decreased hepatic function or decompensation, irrespective of liver enzyme levels.
- •Note: Subjects co-infected with chronic hepatitis B or C will be allowed to enter the trial if their condition is clinically stable and is not expected to require treatment during the study period. Subjects diagnosed with acute viral hepatitis at screening will not be allowed in the trial. Please refer to the package insert with respect to proper care of hepatitis B co-infection in case tenofovir and emtricitabine are included in the OBR.
- •11. Any active clinically significant disease (e.g., TB, cardiac dysfunction, pancreatitis, acute viral infections) or findings during screening of medical history or physical examination that, in the investigator’s opinion, would compromise the subjects safety or outcome of the study.
- •12. Subjects with a grade 3 or 4 laboratory abnormality as defined by DAIDS grading scheme, with the following exceptions unless clinical assessment foresees an immediate health risk to the subject:
- •Subjects with pre-existing
研究者
相似试验
进行中（未招募）
1 期
A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1 infected subjects. - This trial will be referred to as ARTEMIS.EUCTR2005-002486-36-GBTibotec Pharmaceuticals Limited
进行中（未招募）
不适用
A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1 infected subjects. - This trial will be referred to as ARTEMIS.EUCTR2005-002486-36-BETibotec Pharmaceuticals Limited660
进行中（未招募）
不适用
A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1 infected subjects.A substudy of TMC114-C211 to evaluate the pharmacokinetic profile of TMC114 and RTV at Week 4, 24 and 48, co-administered with a fixed background regimen consisting of TDF and FTC. - This trial will be referred to as ARTEMIS.HIV-1EUCTR2005-002486-36-HUTibotec Pharmaceuticals Limited660
进行中（未招募）
不适用
A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1 infected subjects. - This trial will be referred to as ARTEMIS.EUCTR2005-002486-36-DETibotec Pharmaceuticals Limited660
进行中（未招募）
不适用
A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1 infected subjects. This trial will be referred to as ARTEMIS. - This trial will be referred to as ARTEMIS.HIV-1MedDRA version: 14.1Level: LLTClassification code 10008922Term: Chronic infection with HIVSystem Organ Class: 100000004862EUCTR2005-002486-36-ITJANSSEN R&D IRELAND660